Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury

Acute kidney injury (AKI) is a condition with a poor prognosis, exacerbated by the lack of effective therapeutic options and inadequately understood underlying mechanisms. Glycosylation, a post-translational modification of proteins, is essential for maintaining protein stability and function, and i...

Full description

Saved in:
Bibliographic Details
Main Authors: Pei Xie, Huijun Liu, Xingli Huo, Junlong Chen, Yu Li, Yu Huang, Zongning Yin
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/17/3/145
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849339890784796672
author Pei Xie
Huijun Liu
Xingli Huo
Junlong Chen
Yu Li
Yu Huang
Zongning Yin
author_facet Pei Xie
Huijun Liu
Xingli Huo
Junlong Chen
Yu Li
Yu Huang
Zongning Yin
author_sort Pei Xie
collection DOAJ
description Acute kidney injury (AKI) is a condition with a poor prognosis, exacerbated by the lack of effective therapeutic options and inadequately understood underlying mechanisms. Glycosylation, a post-translational modification of proteins, is essential for maintaining protein stability and function, and its dysregulation leads to protein misfolding and amyloid aggregation. Glycosylation dynamics are implicated in several pathologies, including inflammation, cancer, and AKI, highlighting the therapeutic potential of regulating glycosylation and preventing aggregation in AKI treatment. This study investigates the effect of nafamostat mesylate (NM) on protein glycosylation and amyloid aggregation in vivo. Using optical spectroscopy and other analytical techniques, we demonstrate that NM restores glycosylation levels and inhibits protein aggregation in aristolochic-acid-induced acute kidney injury. The mechanism likely involves enzymatic modulation that corrects hypoglycosylation and prevents amyloid aggregation, promoting proper protein folding and enhancing its stability. These findings suggest that NM may provide a novel therapeutic strategy for AKI and other glycosylation-related diseases, underscoring the potential for early intervention and treatment of these conditions.
format Article
id doaj-art-ff4e5635ad1d4636b2918ec55befdf6f
institution Kabale University
issn 2072-6651
language English
publishDate 2025-03-01
publisher MDPI AG
record_format Article
series Toxins
spelling doaj-art-ff4e5635ad1d4636b2918ec55befdf6f2025-08-20T03:44:01ZengMDPI AGToxins2072-66512025-03-0117314510.3390/toxins17030145Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney InjuryPei Xie0Huijun Liu1Xingli Huo2Junlong Chen3Yu Li4Yu Huang5Zongning Yin6Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaHaisco Pharmaceutical Group Co., Ltd., Chengdu 611130, ChinaKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Drug Targeting and Drug Delivery System Key Laboratory of Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, ChinaAcute kidney injury (AKI) is a condition with a poor prognosis, exacerbated by the lack of effective therapeutic options and inadequately understood underlying mechanisms. Glycosylation, a post-translational modification of proteins, is essential for maintaining protein stability and function, and its dysregulation leads to protein misfolding and amyloid aggregation. Glycosylation dynamics are implicated in several pathologies, including inflammation, cancer, and AKI, highlighting the therapeutic potential of regulating glycosylation and preventing aggregation in AKI treatment. This study investigates the effect of nafamostat mesylate (NM) on protein glycosylation and amyloid aggregation in vivo. Using optical spectroscopy and other analytical techniques, we demonstrate that NM restores glycosylation levels and inhibits protein aggregation in aristolochic-acid-induced acute kidney injury. The mechanism likely involves enzymatic modulation that corrects hypoglycosylation and prevents amyloid aggregation, promoting proper protein folding and enhancing its stability. These findings suggest that NM may provide a novel therapeutic strategy for AKI and other glycosylation-related diseases, underscoring the potential for early intervention and treatment of these conditions.https://www.mdpi.com/2072-6651/17/3/145nafamostat mesylateacute kidney injuryglycosylationprotein foldingaristolochic acid
spellingShingle Pei Xie
Huijun Liu
Xingli Huo
Junlong Chen
Yu Li
Yu Huang
Zongning Yin
Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
Toxins
nafamostat mesylate
acute kidney injury
glycosylation
protein folding
aristolochic acid
title Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
title_full Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
title_fullStr Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
title_full_unstemmed Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
title_short Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
title_sort nafamostat mesylate regulates glycosylation to alleviate aristolochic acid induced kidney injury
topic nafamostat mesylate
acute kidney injury
glycosylation
protein folding
aristolochic acid
url https://www.mdpi.com/2072-6651/17/3/145
work_keys_str_mv AT peixie nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT huijunliu nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT xinglihuo nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT junlongchen nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT yuli nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT yuhuang nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury
AT zongningyin nafamostatmesylateregulatesglycosylationtoalleviatearistolochicacidinducedkidneyinjury